DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2008
INDEX
CAPOTEN (captopril), 732–733, 797
Capreomycin, 1563
CAPROGEL (aminocaproic acid), 1792
Capsaicin
FDA-approved indications for,
1830
formulations, 1830
mechanism of action of, 1830
for pruritus, 1828t
structure of, 1830
CAPSIN (capsaicin), 1830
Captopril, 732–733
as antihypertensive agent, 774t,
784–785
for heart failure, 797
history of, 731
in renal failure, 735
structure of, 732f
therapeutic uses of, 738–745
CAR. See Constitutive androstane
receptor (CAR)
CARAC (5-fluorouracil), 1821
Carbachol
acetylcholine vs., 222
in ocular surgery, 1788
for ophthalmic use, 1788
pharmacological properties of, 223t
structure of, 222f
therapeutic use of, 224
Carbamate inhibitors, reversible, 242.
See also Anticholinesterase
agents; specific agent
Carbamazepine, 594–595
metabolism of, 128t, 130, 131f
pharmacokinetics of, 1819t
polymorphisms and response to,
160t
for pruritus, 1828t
and vasopressin secretion, 704
Carbapenems, 1499–1501
Carbenicillin
activity of, 1484
chemistry of, 1479t
properties of, 1479t
Carbenicillin indanyl
chemistry of, 1479t
properties of, 1479t
Carbetocin, 1850
Carbidopa, pharmacokinetics of, 1819t
Carbidopa/levodopa
dosage of, 614t
therapeutic uses of, for
parkinsonism, dosage of,
614t
Carbinoxamine maleate, 921t
Carbohydrate plasma expanders,
histamine and, 914
Carbon dioxide, 561–562
Carbonic anhydrase inhibitors,
677–681
absorption and elimination of, 680
chemistry, 679t
drug interactions with, 680
excretory and renal hemodynamic
effects of, 678t
mechanism of action of, 678–679,
679f
pharmacology of, 679t
and renal hemodynamics, 680
site of action of, 678–679
structure of, 679t
toxicity, adverse effects, and
contraindications to, 680
and urinary excretion, 679–680
Carbonic anhydrase inhibitors (CAIs),
for glaucoma, 1787
Carbon monoxide, in central nervous
system, 390
Carbon monoxide antidote, 86t
Carboplatin, 1668t–1670t, 1689
extramedullary toxicity of, 1682t
pharmacokinetics of, 1820t
Carboxylestrases, 131
Carboxypeptidase M, 929–930
Carboxypeptidase N, 929
Carcinogen(s), 1855–1860
Carcinogensis, 1855–1857
Carcinoid, malignant, drugs for,
1668t–1670t
CARDENE (nicardipine), 762t
Cardiac action potentials. See Action
potential(s), cardiac
Cardiac arrhythmias
ethanol and, 636
sympathomimetic drugs for, 302
Cardiac Arrhythmia Suppression Trial
(CAST), 832
Cardiac cell, 815–816, 816f
sodium and calcium exchange in,
802f
Cardiac conduction
decremental, 819
factors affecting, 819
failure, 819
Cardiac electrophysiology, 815–819
action potentials in, 816–817
heterogeneity of, 817–818
conduction failure and, 819, 819f
impulse propagation, 818–819
impulse propagation and ECG, 818f
Cardiac electrophysiology (Cont.):
maintenance of intracellular ion
homeostasis in, 818
as “moving target” for therapy, 833
refractoriness, 819, 819f, 826f
sodium and calcium exchange in,
802f
Cardiac glycoside antidote, 86t
Cardiac glycosides, 801–804, 837–839
electrophysiologic actions, 803
for heart failure, 801–804
inhibition of Na,K-ATPase, 801
mechanism of action of, 801–803
pharmacokinetics of, 803
positive inotropic effect, 802–803
regulation of sympathetic nervous
system activity, 803
toxicity of, 803–804
Cardiomyopathy
ethanol and, 636
hypertrophic, angina pectoris with,
recommended treatment for,
769t
Cardioprotection, NSAIDs for,
971–972
Cardiovascular disease (CVD), risk
assessment
for men, 888t
for women, 889t
Cardiovascular system
acetylcholine and, 220–221
adrenocorticosteroids and,
1220–1221
atropine and, 233
beta-adrenergic receptor antagonists
and, 313–314, 316
choline esters and, 223t
dobutamine and, 290
dopamine and, 288
drug effects on
prostaglandin, 946–947
thromboxane, 946–947
eicosanoids and, 948–949
ethanol and, 635–636
fentanyl and, 507
ganglionic blocking drugs and, 273
halothane and, 546–547
histamine and, 916
isoflurane and, 548
kinins and, 931
meperidine and, 506
muscarinic antagonists and,
227–228, 233
nicotine and, 271
norepinephrine and, 287